A digital guardian angel enhancing cancer patient’s wellbeing and health status improvement following treatment.

ended

The burden of cancer is rising globally and is estimated to have reached 18.1 million new cases and 9.6 million cancer deaths in 2018. Despite the rising cancer incidence, improvements in early detection and therapeutic treatment have improved cancer survival. As a consequence, the number of cancer survivors is increasing globally, creating the need to improve not only treatment but also wellness and follow‐up care. Cancer treatment often involves combined modalities such as surgery, chemotherapy, and radiotherapy. In the past decades, more effective and targeted therapeutic modalities and less destructive cancer treatments have been developed such as immunotherapy and drug‐targeted therapy. Even so, cancer and its treatment have important physical and psychosocial sequelae. ONCORELIEF is a 36-month action that will leverage the above 6 drivers in order to skillfully and methodologically overcome technical challenges, by introducing new approaches that will allow the utilization of big datasets in order to develop a user-centered AI System to facilitate the integration of QoL assessment instruments through the use of PROMs and PREMs in order to improve post-treatment health status, increase the wellbeing, and follow‐up care of cancer patients. This will be achieved through an intuitive smart digital assistant (Guardian Angel), able to provide personalized support in post-treatment activities and tasks, suggest actions regarding the patients' overall health-status, improved wellbeing and active health-care and ultimately maintain him/her engaged on a wellness journey that will safeguard his/her health over the foreseeable prolonged post-cancer treatment period. To achieve this, ONCORELIEF builds on the combined knowhow of its interdisciplinary industry-driven consortium that brings together state-of-the-art technological skills, design thinking methodology and occupational psychology/health sciences.